Last reviewed · How we verify
Arm T1: Primatene Mist HFA
Arm T1: Primatene Mist HFA is a Sympathomimetic agent Small molecule drug developed by Amphastar Pharmaceuticals, Inc.. It is currently in Phase 2 development for Relief of acute asthma symptoms, Relief of acute bronchospasm in COPD. Also known as: epinephrine inhalation aerosol.
Primatene Mist HFA is a bronchodilator that contains epinephrine, which works by relaxing the muscles in the airways and increasing air flow to the lungs.
Primatene Mist HFA is a bronchodilator that contains epinephrine, which works by relaxing the muscles in the airways and increasing air flow to the lungs. Used for Relief of acute asthma symptoms, Relief of acute bronchospasm in COPD.
At a glance
| Generic name | Arm T1: Primatene Mist HFA |
|---|---|
| Also known as | epinephrine inhalation aerosol |
| Sponsor | Amphastar Pharmaceuticals, Inc. |
| Drug class | Sympathomimetic agent |
| Target | beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Epinephrine is a sympathomimetic agent that stimulates the beta-2 adrenergic receptors in the lungs, causing bronchodilation. This helps to relieve bronchospasm and improve breathing in patients with asthma or chronic obstructive pulmonary disease (COPD).
Approved indications
- Relief of acute asthma symptoms
- Relief of acute bronchospasm in COPD
Common side effects
- Tremors
- Nervousness
- Palpitations
- Headache
- Dizziness
Key clinical trials
- Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers (PHASE1, PHASE2)
- Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients. (PHASE1, PHASE2)
- Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm T1: Primatene Mist HFA CI brief — competitive landscape report
- Arm T1: Primatene Mist HFA updates RSS · CI watch RSS
- Amphastar Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Arm T1: Primatene Mist HFA
What is Arm T1: Primatene Mist HFA?
How does Arm T1: Primatene Mist HFA work?
What is Arm T1: Primatene Mist HFA used for?
Who makes Arm T1: Primatene Mist HFA?
Is Arm T1: Primatene Mist HFA also known as anything else?
What drug class is Arm T1: Primatene Mist HFA in?
What development phase is Arm T1: Primatene Mist HFA in?
What are the side effects of Arm T1: Primatene Mist HFA?
What does Arm T1: Primatene Mist HFA target?
Related
- Drug class: All Sympathomimetic agent drugs
- Target: All drugs targeting beta-2 adrenergic receptor
- Manufacturer: Amphastar Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Relief of acute asthma symptoms
- Indication: Drugs for Relief of acute bronchospasm in COPD
- Also known as: epinephrine inhalation aerosol
- Compare: Arm T1: Primatene Mist HFA vs similar drugs
- Pricing: Arm T1: Primatene Mist HFA cost, discount & access